Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

Delayed Quote. Delayed  - 10/21 10:00:33 pm
87.41 USD   +0.13%
10/21 CVS HEALTH : Pay goes live nationwide
10/20 CVS HEALTH : Safe Drug Disposal is Key to Preventing Abuse
10/20 CVS HEALTH : Announces 47 Metric Tons of Unwanted Medication Collect..
News SummaryMost relevantAll newsSector news 

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2013 | 05:11pm CEST

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Purchased Brazil drugstore chain Drogaria Onofre last week

(Updates with details about an acquisition and other comments made during a conference call, beginning in the seventh paragraph.)

   By John Kell 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

In a conference call with analysts, CVS disclosed it purchased Brazil drugstore chain Drogaria Onofre last week, though no price tag was disclosed as CVS called the deal "not financially material."

CVS will acquire 44 locations through the deal, the company's first acquisition abroad. The purchase comes more than six months after Walgreen agreed to spend $6.7 billion to buy a 45% stake in European pharmacy operator Alliance Boots.

CVS said it views Brazil as an attractive market, saying that region's health-care and pharmacy segments should grow in double digits for the next decade.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Walgreen has sought to strengthen its core business with its new loyalty-card program and by selling more private-label offerings. CVS on Wednesday indicated it is staying focused on retaining customer loyalty by launching more targeted promotions and e-mail offers.

CVS last week launched a pharmacy rewards program to promote retention and better prescription adherence. CVS has also doubled the amount of e-mails it sends and is seeing greater interest in the beauty-product deals it offers. Overall, CVS posted a 19% jump in the amount of offers redeemed by consumers last year.

CVS shares were down 0.2% to $51.61 in recent trading. The stock is up 6.7% in 2013.

  --Tess Stynes contributed to this article 

Write to John Kell at john.kell@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH CORP
10/21 CVS HEALTH : Pay goes live nationwide
10/20 CVS HEALTH : SilverScript Insurance Company, a CVS Health Company, Introduces Ne..
10/20 WOMENHEART : The National Coalition for Women with Heart Disease Receives Commun..
10/20 CVS HEALTH : Safe Drug Disposal is Key to Preventing Abuse
10/20 CVS HEALTH : Announces 47 Metric Tons of Unwanted Medication Collected Through S..
10/20 CVS HEALTH : Dorchester Wealth Management Co buys $5,458,536 stake in CVS Health..
10/20 CVS HEALTH : Pharmacy Takes Pay Nationwide Following Successful Pilot
10/20 CVS HEALTH CORP : ex-dividend day
10/19 CVS HEALTH : Pharmacy to Help Patients Understand Health Insurance Options Durin..
10/19 CVS CAREMARK : How Competition Can Increase Access and Reduce Costs
More news
Sector news : Drug Retailers - NEC
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJWalgreens, Rite Aid Push Back Merger Deadline -- Update
10/20 Walgreens sees Rite Aid deal closing in early 2017
10/20DJWALGREENS BOOTS ALLIANCE : Rite Aid Push Back Merger Deadline
10/10DJWALGREENS BOOTS ALLIANCE : Major Investor Sues Theranos
More sector news : Drug Retailers - NEC
News from SeekingAlpha
10/20 The Drug Battle Coming To A Neighborhood Near You
10/19 The Attractiveness Of CVS At $86 Instead Of $106
10/19 CVS : Garage Sale Bargain
10/19 CVS HEALTH CORPORATION : Attractively Valued And Set Up For Double Digit Returns
10/19 Buy CVS Health - Cramer's Lightning Round (10/18/16)
Financials ($)
Sales 2016 179 801 M
EBIT 2016 10 816 M
Net income 2016 5 730 M
Debt 2016 24 813 M
Yield 2016 1,88%
P/E ratio 2016 16,76
P/E ratio 2017 14,09
EV / Sales 2016 0,66x
EV / Sales 2017 0,60x
Capitalization 93 198 M
More Financials
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 108 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-10.60%93 198
More Results